Dasatinib for Glioblastoma

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Tom Baker Cancer Centre, Calgary, Canada
Glioblastoma+3 More
Dasatinib - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This will be a single-arm open-label prospective pilot feasibility trial recruiting 10 adult patients with recurrent glioblastoma who are assigned to receive the personalized study treatment based on the genetic profile of their recurrent GBM tumor resected at the time of surgery. It will be aimed to gather preliminary information on the study intervention and the feasibility of conducting a full-scale trial.

Eligible Conditions

  • Glioblastoma
  • Recurrent Glioblastoma
  • Recurrent Disease

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 4 Secondary · Reporting Duration: From date of study drug administration until date of radiographic confirmed progression (approximately 2 years)

Baseline until the end of treatment
Quality of Life (QoL) EORTC QLQ BN-20
Quality of Life (QoL) EORTC QLQ-C30
Month 24
Correlation of genomic and expression profiling of tissue and organoid with the organoid's best drug response
Feasibility of implementation of personalized GBM treatment based on molecular characterization of recurrent tumor
Genomic and expression profiling
Organoid drug response
Month 24
Success rate of personalized GBM treatment based on molecular characterization of recurrent tumor
Month 24
Overall survival (OS)
Year 2
Progression free survival (PFS)

Trial Safety

Trial Design

1 Treatment Group

Treatment
1 of 1
Experimental Treatment

10 Total Participants · 1 Treatment Group

Primary Treatment: Dasatinib · No Placebo Group · Phase < 1

TreatmentExperimental Group · 6 Interventions: Afatinib, Dasatinib, Palbociclib, Everolimus, Olaparib, Everolimus, Olaparib, Dasatinib, Afatinib, Palbociclib · Intervention Types: Drug, Drug, Drug, Drug, Drug, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Everolimus
2010
Completed Phase 4
~1500
Olaparib
2017
Completed Phase 4
~2060
Dasatinib
2012
Completed Phase 2
~1890
Afatinib
2013
Completed Phase 4
~2270
Palbociclib
2017
Completed Phase 3
~4210

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: from date of study drug administration until date of radiographic confirmed progression (approximately 2 years)
Closest Location: Tom Baker Cancer Centre · Calgary, Canada
Photo of tom baker cancer centre  1Photo of tom baker cancer centre  2Photo of tom baker cancer centre  3
2011First Recorded Clinical Trial
9 TrialsResearching Glioblastoma
180 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a performance status of 2 or less.
You have provided informed consent prior to initiation of any study specific activities/procedures.
Note: abstinence is acceptable if this is established and preferred contraception for the patient and is accepted as a local standard.
Females must not be breastfeeding, throughout the study period up to 180 days after the last dose of study intervention.
Male patients should agree to not donate sperm during the study for at least 6 months until discontinuation of study drug.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.